Literature DB >> 18495645

Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.

Richard S E Keefe1, Philip D Harvey.   

Abstract

Multisite clinical trials aimed at cognitive enhancement across various neuropsychiatric conditions have employed standard neuropsychological tests as outcome measures. While these tests have enjoyed wide clinical use and have proven reliable and predictive of functional disability, a number of implementation challenges have arisen when these tests are used in clinical trials. These issues are likely to be magnified in future studies when cognitive neuroscience (CN) procedures are explored in these trials, because in their current forms CN procedures are less standardized and more difficult to teach and monitor. For multisite trials, we anticipate that the most challenging issues will include assuring tester competence, monitoring tester performance, specific challenges with complex assessment methods, and having resources available for adequate monitoring of data quality. Suggestions for overcoming these implementation challenges are offered.

Entities:  

Mesh:

Year:  2008        PMID: 18495645      PMCID: PMC2632463          DOI: 10.1093/schbul/sbn042

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  13 in total

1.  A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis.

Authors:  Dwight Dickinson; J Daniel Ragland; Monica E Calkins; James M Gold; Ruben C Gur
Journal:  Schizophr Res       Date:  2006-04-17       Impact factor: 4.939

Review 2.  Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.

Authors:  P D Harvey; R S Keefe
Journal:  Am J Psychiatry       Date:  2001-02       Impact factor: 18.112

3.  Baseline neurocognitive deficits in the CATIE schizophrenia trial.

Authors:  Richard S E Keefe; Robert M Bilder; Philip D Harvey; Sonia M Davis; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; Del D Miller; Jose M Canive; Lawrence W Adler; Theo C Manschreck; Marvin Swartz; Robert Rosenheck; Diana O Perkins; Trina M Walker; T Scott Stroup; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2006-04-19       Impact factor: 7.853

Review 4.  Cognitive impairment as a target for pharmacological treatment in schizophrenia.

Authors:  M Davidson; R S Keefe
Journal:  Schizophr Res       Date:  1995-09       Impact factor: 4.939

5.  Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.

Authors:  Philip D Harvey; Jonathan Rabinowitz; Marielle Eerdekens; Michael Davidson
Journal:  Am J Psychiatry       Date:  2005-10       Impact factor: 18.112

6.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

Authors:  R S Keefe; S G Silva; D O Perkins; J A Lieberman
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

7.  Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia.

Authors:  S Kristian Hill; John A Sweeney; Robert M Hamer; Richard S E Keefe; Diana O Perkins; Hongbin Gu; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  J Int Neuropsychol Soc       Date:  2008-03       Impact factor: 2.892

8.  The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.

Authors:  Richard S E Keefe; Terry E Goldberg; Philip D Harvey; James M Gold; Margaret P Poe; Leigh Coughenour
Journal:  Schizophr Res       Date:  2004-06-01       Impact factor: 4.939

9.  The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients.

Authors:  B A Cornblatt; M F Lenzenweger; L Erlenmeyer-Kimling
Journal:  Psychiatry Res       Date:  1989-07       Impact factor: 3.222

10.  Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.

Authors:  Richard S E Keefe; Larry J Seidman; Bruce K Christensen; Robert M Hamer; Tonmoy Sharma; Margriet M Sitskoorn; Richard R J Lewine; Deborah A Yurgelun-Todd; Ruben C Gur; Mauricio Tohen; Gary D Tollefson; Todd M Sanger; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2004-06       Impact factor: 18.112

View more
  6 in total

Review 1.  CNTRICS final task selection: working memory.

Authors:  Deanna M Barch; Marc G Berman; Randy Engle; Jessica Hurdelbrink Jones; John Jonides; Angus Macdonald; Derek Evan Nee; Thomas S Redick; Scott R Sponheim
Journal:  Schizophr Bull       Date:  2008-11-05       Impact factor: 9.306

2.  Performance-based assessment of functional skills in severe mental illness: results of a large-scale study in China.

Authors:  Belinda J McIntosh; Xiang Yang Zhang; Thomas Kosten; Shu Ping Tan; Mei Hong Xiu; Jeffrey Rakofsky; Philip D Harvey
Journal:  J Psychiatr Res       Date:  2011-03-02       Impact factor: 4.791

Review 3.  Memory-prediction errors and their consequences in schizophrenia.

Authors:  Michael S Kraus; Richard S E Keefe; Ranga K R Krishnan
Journal:  Neuropsychol Rev       Date:  2009-07-03       Impact factor: 7.444

4.  Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting.

Authors:  Deanna M Barch; Cameron S Carter; Amy Arnsten; Robert W Buchanan; Jonathan D Cohen; Mark Geyer; Michael F Green; John H Krystal; Keith Nuechterlein; Trevor Robbins; Steven Silverstein; Edward E Smith; Milton Strauss; Til Wykes; Robert Heinssen
Journal:  Schizophr Bull       Date:  2008-11-20       Impact factor: 9.306

Review 5.  Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

Authors:  Richard S E Keefe; Robert W Buchanan; Stephen R Marder; Nina R Schooler; Ashish Dugar; Milana Zivkov; Michelle Stewart
Journal:  Schizophr Bull       Date:  2011-11-22       Impact factor: 9.306

6.  An approach to directly link ICA and seed-based functional connectivity: Application to schizophrenia.

Authors:  Lei Wu; Arvind Caprihan; Juan Bustillo; Andrew Mayer; Vince Calhoun
Journal:  Neuroimage       Date:  2018-06-15       Impact factor: 6.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.